La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Cembra Money Bank a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Cembra Money Bank..

Cembra Money Bank (OTC:CMBNF) Azioni, Catena delle Opzioni

Cembra Money Bank AG is a consumer finance bank operating in Switzerland. The company has two operating segments: Lending and Payments. The company provides financial solutions to its customers. The products offered by the company include consumer credit products such as personal loans, Auto loans and leasing, credit cards, Insurance products, Buy now pay later/invoice financing, and deposits and savings products. The company generates revenue from the Interest Income and Commission and fee income, with the majority of revenue generated from Interest Income. The majority revenue is from Lending Segment.

Cembra Money Bank AG

WIIM

ZBRA

Zebra Technologies shares are trading higher after the company reported better-than-expected Q1 financial results.

News

Guidance

FOUR

Shift4 Payments Sees FY25 Gross Revenue Less Network Fees Of $166B - $1.73B

NeoGenomics Raises FY2025 Adj EPS Guidance from $0.15-$0.19 to $0.16-$0.20 vs $0.18 Est

Stephens &amp; Co. analyst Daniel Imbro downgrades Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) from Overweight to Equal-Weight and lowers the price target from $515 to $255.

Downgrades

Price Target

Analyst Ratings

SAIA

Stephens & Co. Downgrades Saia to Equal-Weight, Lowers Price Target to $255

BBVA

Banco Bilbao Vizcaya Argentaria shares are trading lower. The company reported Q1 financial results.

Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.71 by 50.7 percent. This is a 98.15 percent increase over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $848.30 million which missed the analyst consensus estimate of $868.30 million by 2.30 percent. This is a 19.92 percent increase over sales of $707.40 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Shift4 Payments Q1 Adj. EPS $1.07 Beats $0.71 Estimate, Sales $848.30M Miss $868.30M Estimate

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/04/28/final-trades-goldman-sachs-apollo-global-qualcomm-and-check-point.html">Halftime Report Final Trades</a>,&#8221; Stephen L. Weiss of Short Hills Capital Partners named The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) as <a href="https://www.benzinga.com/quote/GS/earnings">his final trade</a>.
On the earnings front, Goldman Sachs reported quarterly earnings of $14.12 per share on April 14, beating the analyst consensus estimate of $12.35 per share. The firm also reported quarterly sales of $15.06 billion, beating the analyst consensus estimate of $14.81 billion.
Bryn Talkington, Managing Partner of Requisite Capital Management, said Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) will release earnings this Friday.
Analysts expect the company to report quarterly earnings at $1.85 per share on revenue of $964.53 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Jim Lebenthal of Cerity Partners picked QUALCOMM Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) as his final trade, which is scheduled to release earnings results for its second quarter on Wednesday, April 30, after the closing bell.
Analysts expect the company to report quarterly earnings at $2.81 per share on revenue of $10.65 billion.
Joseph M. Terranova of Virtus Investment Partners picked Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>) after last week's selloff following earnings report.
On April 23, the company reported quarterly revenue growth of 7% year over year to $637.8 million, topping the analyst consensus estimate of $636.2 million.
Price Action:
<ul>
<li>Goldman Sachs shares gained 0.3% to close at $546.40 on Monday.</li>
<li>Apollo Global gained 2.2% to close at $136.36 during Monday's session.</li>
<li>Qualcomm shares fell 0.6% to close at $147.62 on Monday.</li>
<li>Check Point Software shares climbed 2.8% to settle at $212.41 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Markets

Media

Trading Ideas

CHKP

QCOM

Goldman Sachs, Qualcomm, Apollo Global And A Tech Stock On CNBC's 'Final Trades'

Novel Gene Therapy Program Offers a Promising Opportunity for Curative Therapy in Diabetes
AUSTIN, Texas, April 29, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4415379-1&amp;h=3725234881&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming American Society of Gene and Cell Therapy's (ASGCT) 28th Annual Meeting being held May 13-17, 2025 in New Orleans, Louisiana. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.

GNPX

Genprex Collaborators To Present Preclinical Data And Research From Studies Of GPX-002, Diabetes Gene Therapy, At ASGCT 28Th Annual Meeting

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading higher after the company announced a collaboration with Novo Nordisk to offer a bundled package of all dose strengths of Wegovy on its platform.

As President Donald Trump marks 100 days in office, four tech giants who backed his second term have seen their fortunes and their companies&#8217; stock values take a hit. 
What Happened: Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk, Amazon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Founder Jeff Bezos, Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg, and Nvidia CEO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Jensen Huang who have donated or attended Trump&#8217;s inauguration have collectively lost nearly $195 billion since Jan. 20, as per Bloomberg Billionaire Index.
Musk, serves as an advisor to the Trump administration, has experienced the most significant wealth decline of $114 billion, despite remaining the world&#8217;s richest person. After protests targeting Tesla Inc. Musk announced last week that he will scale back his involvement with the White House DOGE office in May. Tesla shares have fallen nearly 25% this year after underwhelming quarterly earnings.
Bezos's fortune—mostly linked to his Amazon Inc shares—has dropped $36 billion since January 20. Analysts say Amazon is especially exposed to Trump's trade war and the 145% tariff on China due to the high volume of Chinese goods sold on its platform.
Zuckerberg's fortune, tied to Meta Platforms, is under pressure as the company faces a government antitrust lawsuit. At the same time, Huang's wealth—largely based on Nvidia Corporation stock—has taken a hit since his appearance at the inauguration. Nvidia shares are down over 21% year to date, and the company expects a $5.5 billion blow to first-quarter earnings due to Trump's restrictions on chip exports to China.
The news was <a href="https://www.businessinsider.com/tech-billionaires-wealth-dropped-trump-100-days-inauguration-2025-4">first</a> reported by Business Insider.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/events/25/04/44971154/trump-fails-to-impress-americas-young-shows-poll-as-they-still-favor-biden-only-15-think-us-on-right-track" target="_blank" rel="noreferrer noopener">Trump Fails To Impress America&#8217;s Young, Shows Poll As They Still Favor Biden — Only 15% Think US On Right Track &#8211; Benzinga</a>
Why It Matters: Trump&#8217;s reciprocal tariffs have threatened to undermine <a href="https://www.benzinga.com/25/04/44641631/trumps-reciprocal-tariffs-threaten-to-derail-big-techs-billion-dollar-ai-infrastructure-plans-analysts-warn-stargate-was-already-unlikely-to-get-to-that-scale">billion-dollar</a> AI infrastructure projects being spearheaded by leading tech companies. These tariffs have been described as &#8216;Armageddon&#8217; for the sector, with tech leaders who backed Trump losing a <a href="https://www.benzinga.com/personal-finance/25/04/44884750/tech-leaders-who-backed-trump-have-lost-1-8-trillion-tariffs-described-as-armageddon-for-the-sector">combined </a>$1.8 trillion due to tariffs by April 18. 
Furthermore, the European Commission president Ursula von der Leyen <a href="https://www.benzinga.com/markets/25/04/44784857/eu-threatens-additional-taxes-on-us-tech-giants-amid-ongoing-tariff-war-we-are-developing-retaliatory-measures-says-von-der-leyen">warned </a>that big U.S. tech firms could end up paying up if Trump tariff talks collapse, EU threatened additional taxes on American tech giants amid ongoing trade war.
Meanwhile, according to a CNN poll, Donald Trump&#8217;s 41% approval rating is the lowest of any newly elected president at the 100-day mark since Dwight Eisenhower — even lower than during Trump's first term.
Vanguard Information Technology Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGT#NYSE">VGT</a>) declined 12.2% year-to-date while SPDR NYSE Technology ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XNTK#NYSE">XNTK</a>) lost 3.56%.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/tech/25/04/45060194/godfather-of-ai-geoffrey-hinton-backs-elon-musk-in-fight-against-openais-restructuring-id-like-to-stop-them-" target="_blank" rel="noreferrer noopener">&#8216;Godfather Of AI&#8217; Geoffrey Hinton Backs Elon Musk In Fight Against OpenAI&#8217;s Restructuring: &#8216;I&#8217;d Like To Stop Them From Completely Gutting It&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

AMZN

NVDA

TSLA

XNTK

As Trump Completes 100 Days As President, Elon Musk, Jeff Bezos, Mark Zuckerberg And Other Billionaire Backers See $195 Billion Wealth Wipeout Amid Market Turmoil

Wolfe Research analyst Mike Polark downgrades Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) from Outperform to Peer Perform.

PODD

Wolfe Research Downgrades Insulet to Peer Perform

Sherwin-Williams shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results above estimates.

NeoGenomics Raises FY2025 Sales Guidance from $735.00M-$745.00M to $747.00M-$759.00M vs $739.39M Est

General

NEHC

New Era Helium Gets Approval  For 120 Miles Of Rights-Of-Way (ROW) In Pecos Slope Field, Permian Basin

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) lowers FY2025 Adj EPS guidance from $1.67-$1.76 to $1.63-$1.72 vs $1.71 analyst estimate. Raises FY2025 sales outlook from $685.00 million-$710.00 million to $695.00 million-$720.00 million vs $700.43 million estimate.

RGEN

Repligen Lowers FY2025 Adj EPS Guidance from $1.67-$1.76 to $1.63-$1.72 vs $1.71 Est; Raises FY2025 Sales Guidance from $685.00M-$710.00M to $695.00M-$720.00M vs $700.43M Est

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) lowers FY2025 GAAP EPS guidance from $0.90-$0.99 to $0.76-$0.85 vs $0.90 analyst estimate. Raises FY2025 sales outlook from $685.00 million-$710.00 million to $695.00 million-$720.00 million vs $700.43 million estimate.

Repligen Lowers FY2025 GAAP EPS Guidance from $0.90-$0.99 to $0.76-$0.85 vs $0.90 Est; Raises FY2025 Sales Guidance from $685.00M-$710.00M to $695.00M-$720.00M vs $700.43M Est

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease.
<ul>
<li>Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo.
<ul>
<li>Six of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p&lt;0.05).
<ul>
<li>This level of symptom clearing has not been achieved by any FDA-approved therapy for dry eye disease.</li>
</ul>
</li>
<li>Symptom Composite Score (a measure of dry eye symptom improvement) for PL9643-treated patients showed:
<ul>
<li>Statistically significant symptom resolution by week 2.</li>
<li>Continued improvement through week 12 with no plateau.</li>
<li>In contrast, placebo-treated patients showed minimal improvement that&nbsp;plateaued early.</li>
</ul>
</li>
<li>FDA approval guidance (2020) supports the use of responder analysis to demonstrate symptom improvement.
<ul>
<li>This includes showing a statistically significant difference in the percentage of patients achieving complete resolution of a symptom&nbsp;— a threshold PL9643 met across multiple symptom endpoints.</li>
</ul>
</li>
</ul>
</li>
</ul>

Biotech

Health Care

Palatin Technologies Announced Updated Results From Responder Analyses Of Its Pivotal Phase 3 MELODY-1 Trial Evaluating The Safety And Efficacy Of Pl9643 Versus Placebo For Dry Eye Disease

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RINVOQ (upadacitinib) is now the first and only oral Janus Kinase (JAK) inhibitor approved for the treatment of GCA in adults –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Also known as temporal arteritis, GCA is the most common vasculitis affecting adults in Western countries2 –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This marks the ninth approved indication for RINVOQ in the U.S., across rheumatology, gastroenterology, and dermatology1
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ&#xAE; (upadacitinib), 15 mg, once daily,&nbsp;for the treatment of adults with giant cell arteritis (GCA).1 This comes after the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4413188-1&amp;h=3024659070&amp;u=https%3A%2F%2Fnews.abbvie.com%2F2025-04-08-AbbVie-Announces-European-Commission-Approval-of-RINVOQ-R-upadacitinib-for-the-Treatment-of-Adults-with-Giant-Cell-Arteritis&amp;a=European+Commission">European Commission</a> recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.&nbsp;
The approvals are supported by results of the pivotal Phase 3 SELECT-GCA clinical trial, which met the primary endpoint of sustained remission&#x2A; (46.4% of patients receiving RINVOQ 15 mg in combination with a 26-week steroid taper regimen achieved sustained remission from week 12 to week 52, compared to 29.0% of patients receiving placebo in combination with a 52-week steroid taper regimen; p=0.002).1
During the 52-week, placebo-controlled period, the safety profile of RINVOQ was generally consistent with that observed in other approved indications.

ABBV

Abbvie: FDA Approves RINVOQ, 15 Mg, Once Daily, For Treatment Of Adults With Giant Cell Arteritis

SENS

Sequel Med Tech Inks Commercial Development Agreement With Senseonics To Integrate Sequel's twiist Automated Insulin Delivery (AID)

As a first step, Americans can now access NovoCare Pharmacy directly through the Hims &amp; Hers platform, with a bundled offering of all dose strengths of Wegovy and a Hims &amp; Hers membership, which includes access to 24/7 care, ongoing clinical support, and nutrition guidance, all in one place. At a single, unified price starting at 599 USD per month, individuals may be prescribed Wegovy&#xAE;, alongside Hims &amp; Hers' world-class, holistic approach to care, powered by today's technology. The offering is available this week on the Hims &amp; Hers platform.
The companies are also developing a roadmap that combines Novo Nordisk's innovative treatments with Hims &amp; Hers' ability to scale access to quality care, aiming to improve long-term outcomes for more people, more affordably.

Large Cap

Contracts

Novo Nordisk And Hims & Hers Health Announced A Long-term Collaboration For A Bundled Offering Of Novo Nordisk's FDA-Approved Wegovy On The Hims & Hers Platform

Cembra Money Bank

Comments

Cembra Money Bank

Cembra Money Bank (CMBNF) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO